Announcement • Jun 27
Zomedica Announces Issuance of Additional Patent for its TRUVIEW Microscope Zomedica Corp. announced the issuance of a new patent related to its TRUVIEW microscope and provided an update on the Company's current intellectual property portfolio. The U.S. Patent related to the TRUVIEW microscope, manufactured, sold and distributed by Zomedica, was U.S. Patent No. 12,299,917 B2 issued recently for the Methods and Systems for Slide Imaging Calibration. Announcement • May 10
Zomedica Corp. to Report Q1, 2025 Results on May 15, 2025 Zomedica Corp. announced that they will report Q1, 2025 results on May 15, 2025 Announcement • Mar 05
NYSE American to Commence Delisting Proceedings Against Zomedica Corp NYSE American LLC (“NYSE American” or the “Exchange”) announced that the staff of NYSE Regulation has determined to commence proceedings to delist the common shares of Zomedica Corp. (the “Company”) — ticker symbol ZOM — from NYSE American. Trading in the Company’s common shares will be suspended immediately. NYSE Regulation has determined that the Company is no longer suitable for listing pursuant to Section 1003(f)(v) of the NYSE American Company Guide due to the low selling price of the common shares. The Company has a right to a review of the staff’s determination to delist the common shares by the Listings Qualifications Panel of the Committee for Review of the Board of Directors of the Exchange. The NYSE American will apply to the Securities and Exchange Commission to delist the Company’s common shares upon completion of all applicable procedures, including any appeal by the Company of the NYSE Regulation staff’s decision. New Risk • Mar 04
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: US$95.5m This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$29m net loss in 3 years). Market cap is less than US$100m (US$95.5m market cap). Announcement • Feb 26
Zomedica Corp. to Report Q4, 2024 Results on Mar 13, 2025 Zomedica Corp. announced that they will report Q4, 2024 results on Mar 13, 2025 Announcement • Dec 24
Zomedica Corp. Launches Two New Quantitative Assays on the Truforma(R) Platform: Canine NT-proBNP and Progesterone Zomedica Corp. announced the launch of two new canine assays for the TRUFORMA In-Clinic Biosensor Testing Platform. Zomedica's canine NT-poBNP test is used for the quantitative detection of NT-proBNP in canine EDTA plasma or serum. Elevated NT-proBNP can be indicative of conditions such as congestive heart failure, assisting in the diagnosis and management of cardiac conditions in dogs. This test distinguishes cardiac from respiratory disease, identifies dogs at high risk of congestive heart failure, aids with chronic monitoring of dogs with myxomatous mitral valve degeneration all with reference lab accuracy. Zomedica's progesterone testing is used for quantitative detection of the levels of progesterone in canine serum. This will aide in determining optimal breeding dates, predicting parturition dates or timing a cesarean section, and detecting reproductive disorders with the same accuracy as the reference lab but with in-clinic convenience. Zomedica's new progesterone assay has been one of the most frequently requested assays from practitioners, which is unsurprising when there are 4 million puppies born in the US every year. Each of these new offerings deliver quantitative results available in less than 20 minutes with the same high level of precision that TRUFORMA customers have grown accustomed to. Importantly, Zomedica offers this advanced diagnostic capability with no capital outlay or monthly minimums from veterinary practices. Recent Insider Transactions • Nov 14
Senior Vice President of Sales recently bought US$60k worth of stock On the 11th of November, Russell Klass bought around 500k shares on-market at roughly US$0.12 per share. This transaction amounted to 50% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought US$536k more in shares than they have sold in the last 12 months. Announcement • Nov 14
Zomedica Launches Quantitative Insulin Assay for Equine Plasma on the TRUFORMA(R) Platform Zomedica Corp. announced the launch of its third equine-focused assay - Insulin for equine plasma - for the TRUFORMA In-Clinic Biosensor Testing Platform. Veteransinarians test equine insulin levels when they suspect Equine Metabolic Syndrome (EMS) or other forms of insulin dysregulation, as frequently occurs with equine Cushing's disease, or Pituitary Pars Intermedia Dysfunction (PPID), with prevalence reported between 18-27% of horses and horses. Left untreated, laminitis, which can lead to euthanasia, is a consequence of both EMS and PPID. The TRUFORMA Insulin assay offers quantitative detection of insulin levels in equine plasma, with results available in just 18 minutes. This rapid turnaround enables veterinarians to diagnose and monitor insulin dysregulation in horses quickly, eliminating the need for reference laboratory wait times and allowing for immediate treatment decisions. The assay is designed for both in-clinic and stall-side use, providing flexibility for various clinical settings. Importantly, Zomedica offers this advanced diagnostic capability with no capital outlay or monthly minimums from veterinary practices. Reported Earnings • Nov 10
Third quarter 2024 earnings released: US$0.007 loss per share (vs US$0.001 loss in 3Q 2023) Third quarter 2024 results: US$0.007 loss per share (further deteriorated from US$0.001 loss in 3Q 2023). Revenue: US$7.00m (up 10% from 3Q 2023). Net loss: US$6.70m (loss widened US$6.21m from 3Q 2023). Over the last 3 years on average, earnings per share has fallen by 11% per year but the company’s share price has fallen by 39% per year, which means it is performing significantly worse than earnings. Announcement • Oct 25
Zomedica Corp. Launches Ear Cytology Quick Scan Protocol for TRUVIEW Digital Microscope & Telepathology Platform Zomedica Corp. announced the release of the Ear Cytology Quick Scan protocol, a new feature available on the TRUVIEW microscope equipped with the TRUprep™? automated slide preparation system. This innovative feature streamlines the slide preparation and scanning of ear cytology cases, allowing veterinary professionals to diagnose and treat companion animals faster and more efficiently. Ear infections are among the most common reasons for vet visits. The Companion Animal Ear Infection Treatment Market, valued at $648 million in 2023, is projected to grow to $1.2 billion by 2032, with a compounded annual growth rate (CAGR) of 6.8%.titis, a common condition that affects 15-20% of dogs and 4-7% of cats, requires efficient and accurate cytology workflows to diagnose the presence of yeast, bacteria, and inflammation. With the Ear Cytology QuickScan protocol launch, Zomedica reaffirms its commitment to enhancing veterinary care by improving diagnostic tools that optimize clinic workflow and profitability. Announcement • Oct 24
Zomedica Corp. to Report Q3, 2024 Results on Nov 07, 2024 Zomedica Corp. announced that they will report Q3, 2024 results on Nov 07, 2024 Announcement • Aug 29
Zomedica's Assisi Loop Product Line Designated as Fear Free(TM) Preferred Product Zomedica Corp. announced that its Assisi Loop product line is continuing its designation as a Fear Free Preferred Product. Fear Free, a globally recognized initiative dedicated to reducing fear, anxiety, and stress in pets, reaffirmed its validation of Assisi's targeted pulsed electromagnetic field (tPEMF) technology, which is designed to reduce inflammation and pain, accelerate healing, and alleviate canine separation anxiety. Assisi Loop products, including the Assisi Loop Lounge®, are effective for a wide range of inflammatory conditions, including post-surgical recovery, osteoarthritis, internal inflammation, wound care, spinal and nerve disorders, and bone, joint, and soft tissue injuries. The Calmer Canine Anxiety Treatment System® reduces canine anxiety with a tPEMF signal specifically tuned to influence the amygdala, which is the emotional center of the brain. Announcement • Aug 22
Zomedica Corp. Introduces Enhanced Audio Features for the Vetguardian Zero-Touch Vital Signs Remote Monitoring System Zomedica Corp. announced the introduction of advanced audio capabilities for its VETGuardian Zero-touch remote vital signs monitoring system, poised to revolutionize remote patient monitoring in veterinary medicine. These cutting-edge features include real-time audio streaming, recorded playback functionality, and customizable alerts, empowering veterinarians with unparalleled insights into animal health through auditory data. The VetGuardian monitor stands out as the only system on the market offering contactless vital sign monitoring, coupled with a live video and audio feed. This unique combination allows veterinarians to assess animals remotely with unprecedented detail and responsiveness. The ability to review audio recordings allows veterinarians to document vocalizations that may indicate pain, distress, or improvements in recovery over time. This detailed data enhances medical records and provides a comprehensive view of the animal's progress, supporting informed decision-making and enhancing patient care outcomes. From identifying early signs of distress to monitoring treatment responses, the VETGuardian system's advanced audio capabilities enhance veterinary care coordination and decision-making, setting a new standard in animal health monitoring solutions. Reported Earnings • Aug 16
Second quarter 2024 earnings released: US$0.024 loss per share (vs US$0.005 loss in 2Q 2023) Second quarter 2024 results: US$0.024 loss per share (further deteriorated from US$0.005 loss in 2Q 2023). Revenue: US$6.13m (up 1.8% from 2Q 2023). Net loss: US$23.9m (loss widened 356% from 2Q 2023). Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has fallen by 33% per year, which means it is significantly lagging earnings. Announcement • Jun 28
Zomedica Corp. Expands Truforma Addressable Market with Launch of Equine Cortisol Assay for the Platform Zomedica Corp. announced the commercial launch of its second equine focused assay - Cortisol for equine serum - for the point-of-care TRUFORMA®? diagnostic platform. The first days of a foal's life can be the most challenging, as illness during this time can cause a foal's health and survival chances to change rapidly. The TRUFORMA platform addresses a $1.5 billion annual recurring revenue opportunity in the US, and with CE marking secured in June, is now positioned to expand into the European veterinary diagnostics market, which is forecast to surpass $3.6 billion by 2028. The TRUFORMA Cortisol assay for equine serum will be available for veterinarians to order directly from Zomedica in July. Recent Insider Transactions • Jun 13
Senior Vice President of Sales recently bought US$105k worth of stock On the 11th of June, Russell Klass bought around 700k shares on-market at roughly US$0.15 per share. This transaction amounted to 70% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought US$305k more in shares than they have sold in the last 12 months. Announcement • May 16
Zomedica Corp. Releases Over-The-Air Software Update Capabilities for Its Truforma(R) Platform Zomedica Corp. announced the launch of Over-the-Air ("OTA") software and firmware update capabilities for its TRUFORMA point-of-care diagnostic platform. OTA updates will be delivered via Zomedica's myZomedica® cloud customer experience and Internet-of-Things (IoT) platform. OTA capabilities streamline the software update process for both Zomedica and its customers. When a new software update is available, customers will be notified on their device and can apply the update with the push of a button. The myZomedica global OTA service includes best practices capabilities for staged deployments to ensure software update resiliency. Announcement • May 11
Zomedica Corp. Provides Revenue Guidance for Full Year 2024 Zomedica Corp. provided Revenue Guidance for Full Year 2024. For the full year 2024, the Company continues to expect full year revenue in the range of $31 to $35 million, an increase of approximately 39% at the high end of the range, over full year 2023 revenue of $25.2 million. The Company expects that on a quarterly basis, revenues should increase sequentially from the first quarter, with the majority of revenue expected to be recorded during the back half of the year. New Risk • May 11
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 10.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 2.7% per year over the past 5 years. Minor Risk Share price has been volatile over the past 3 months (10.0% average weekly change). Reported Earnings • May 10
First quarter 2024 earnings released: US$0.009 loss per share (vs US$0.007 loss in 1Q 2023) First quarter 2024 results: US$0.009 loss per share (further deteriorated from US$0.007 loss in 1Q 2023). Revenue: US$6.26m (up 14% from 1Q 2023). Net loss: US$9.16m (loss widened 44% from 1Q 2023). Over the last 3 years on average, earnings per share has increased by 45% per year but the company’s share price has fallen by 43% per year, which means it is significantly lagging earnings. Announcement • May 01
Zomedica Corp. to Report Q1, 2024 Results on May 09, 2024 Zomedica Corp. announced that they will report Q1, 2024 results at 4:30 PM, US Eastern Standard Time on May 09, 2024 Announcement • Apr 13
Zomedica Corp., Annual General Meeting, Jun 06, 2024 Zomedica Corp., Annual General Meeting, Jun 06, 2024. Announcement • Apr 03
Zomedica Corp. Provides Revenue Guidance for Full Year 2024 Zomedica Corp. provided revenue guidance for full year 2024. For the period, the company expects revenue in the range of $31 to $35 million, an increase of approximately 40% at the high end of the range, over full year 2023 revenue of $25.2 million. Reported Earnings • Apr 02
Full year 2023 earnings released: US$0.035 loss per share (vs US$0.017 loss in FY 2022) Full year 2023 results: US$0.035 loss per share (further deteriorated from US$0.017 loss in FY 2022). Revenue: US$25.2m (up 33% from FY 2022). Net loss: US$34.5m (loss widened 103% from FY 2022). Over the last 3 years on average, earnings per share has increased by 49% per year but the company’s share price has fallen by 54% per year, which means it is significantly lagging earnings. Announcement • Mar 21
Zomedica Corp. to Report Q4, 2023 Results on Apr 01, 2024 Zomedica Corp. announced that they will report Q4, 2023 results on Apr 01, 2024 New Risk • Jan 22
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 3.3% per year over the past 5 years. Minor Risk Share price has been volatile over the past 3 months (11% average weekly change). Announcement • Jan 18
Zomedica Corp. Provides Revenue Guidance for the Fourth Quarter and Full Year of 2023 and Full Year 2024 Zomedica Corp. provided revenue guidance for the fourth quarter and full year of 2023. Revenue for the fourth quarter of 2023 is expected to be over $7 million, a new record for the Company, compared to record fourth quarter 2022 revenue of $6.2 million.Revenue for 2023 is expected to be over $25 million, an increase of over 32% compared to 2022 revenue of $18.9 million.For the full year 2024, the Company is introducing formal financial guidance, as follows: the Company expects full year revenue in the range of $31 to $35 million, an increase of approximately 40% at the high end of the range, over full year 2023 revenue of over $25 million. Announcement • Dec 18
Zomedica Corp. Announces Expansion of Market Opportunity for TRUFORMA(R) Diagnostic Platform with Launch of Three New Assays for Commonly Performed Diagnostic Tests for Canine Gastrointestinal Disease Zomedica Corp. announced the commercial launch of three new assays: Canine Pancreatic Lipase (cPL), Cobalamin (B12) and Folate, for the TRUFORMA®? In-Clinic Biosensor Testing Platform. offer three of the most common assays for these cases: Canine Pancreatic Lipase (cPL), Cobalamin (B12), and Folate, to help diagnose pancreatitis and irritable bowel disease (IBD), respectively. The company believed through these assays can help veterinarians produce better outcomes for pets and pet parents by providing faster diagnostic solutions, while also streamlining their workflow and increasing practice profitability. For cPL, veterinarians have historically needed to choose between a rapid in-clinic diagnostic and a high-quality reference lab test which typically meant waiting for results until at least the next day. The TRUFORMA cPL test delivers reference lab quality results at the point of care. Announcement • Dec 06
Zomedica Announces Presentation of Clinical Data in Support of New Indications for Pulsevet Shock Wave Therapy Zomedica Corp. announced the presentation of new clinical data supporting new indications for shock wave therapy at the recent meeting of the American Association of Equine Practitioners (AAEP) annual meeting in San Diego, California. Principal Investigator Dr. Beau Whitaker of Brazos Valley Equine Hospital (Salado, TX) presented results from the study showing that barrel racing horses with Exercise Induced Pulmonary Hemorrhage (EIPH) could be successfully treated with PulseVet's electrohydraulic shock wave therapy. In this study more than 75% of the horses treated showed significant improvement following shock wave therapy treatment. Perhaps more significantly, the successful outcomes appear closely tied to asthma and a second study has been initiated focusing entirely on asthmatic horses. Of eight horses treated in the asthma study to date seven of the eight had 100% resolution of coughing in four weeks and the remaining horse had a 50% reduction in coughing. Approximately 15% of horses over the age of seven are affected by asthma which is currently treated by bronchodilators and/or drugs. The study results suggest that shock wave may present a non-invasive, non-pharmacological option for horses suffering from this affliction. In addition to the recent pulmonary findings, Zomedica has initiated research to explore additional benefits, from treating chronic kidney disease in cats and dogs to accelerating hoof growth in horses. One significant study being conducted by Dr. Felix Duerr at Colorado State University (CSU) is evaluating the effectiveness of shock wave therapy in slowing the progression of canine osteoarthritis. Enrollment for this study has been completed and animals will be closely monitored for 50 weeks to assess the long-term impact of the therapy. PulseVet's shock wave therapy harnesses high-energy sound waves to stimulate cells and promote the release of healing growth factors within the body which have been shown to modulate inflammation, enhance blood flow, increase bone density, and accelerate healing. Reported Earnings • Nov 16
Third quarter 2023 earnings released: US$0.001 loss per share (vs US$0.005 loss in 3Q 2022) Third quarter 2023 results: US$0.001 loss per share (improved from US$0.005 loss in 3Q 2022). Revenue: US$6.35m (up 33% from 3Q 2022). Net loss: US$491.0k (loss narrowed 90% from 3Q 2022). Over the last 3 years on average, earnings per share has increased by 55% per year but the company’s share price has only increased by 5% per year, which means it is significantly lagging earnings growth. Announcement • Nov 03
Zomedica Corp. to Report Q3, 2023 Results on Nov 13, 2023 Zomedica Corp. announced that they will report Q3, 2023 results on Nov 13, 2023 Announcement • Oct 06
Zomedica Corp. (NYSEAM:ZOM) acquired Qorvo Biotechnologies, LLC from Qorvo US, Inc. Zomedica Corp. (NYSEAM:ZOM) acquired Qorvo Biotechnologies, LLC from Qorvo US, Inc. on October 5, 2023.
Zomedica Corp. (NYSEAM:ZOM) completed the acquisition of Qorvo Biotechnologies, LLC from Qorvo US, Inc. on October 5, 2023. Announcement • Sep 15
Zomedica Corp. Launches its Newest Assay - Endogenous ACTH Zomedica Corp. announced the commercial launch of its newest assay - endogenous ACTH (eACTH) for equine plasma - for the TRUFORMA In-Clinic Biosensor Testing Platform. PPID or Cushing's disease is one of the most common endocrine disorders in horses and ponies. Left undiagnosed and untreated, quality of life for these animals will rapidly decline and their life expectancy will shorten. The measurement of baseline eACTH is widely accepted as the most effective way to help diagnose PPID and plays an essential role in disease management, but until now, to test eACTH levels, blood samples needed special handling and shipping to remote labs, risking sample degradation or even loss. The TRUFORMA eACTH assay for equine plasma will offer equine veterinarians the ability to diagnose and screen for PPID as well as monitor patients being treated for PPID in their own labs or even stall side in minutes. The TRUFORMA device, being compact, easy to use, and durable, is a great fit for the unique challenges that face equine practitioners. Announcement • Sep 14
Zomedica Receives Non-Compliance Notice from NYSE American Zomedica Corp. ("Zomedica" or the "Company") announced that, as disclosed in its Current Report on Form 8-K filed with the SEC on September 13, 2023 (the "NYSEA Form 8-K"), it has received formal notice from the NYSE American that it is not in compliance with the NYSE American's continued listing standard set in Section 1003(f)(v) of the NYSE American Company Guide because the Company's common shares have been selling for a substantial period of time at a low price per share. The Company's receipt of the notice from the NYSE American does not result in the immediate delisting of the Company's common shares. As disclosed in the NYSEA Form 8-K, the Company plans to notify the NYSE American that it intends to cure the share price deficiency and return to compliance with the NYSE American's continued listing standards by undertaking a measure or series of measures that are for the best interests of the Company and its shareholders. The Company's common shares will continue to be listed and trade on the NYSE American during this period, subject to the Company's compliance with other NYSE American continued listing standards. The notification does not affect the Company's SEC reporting requirements or the ongoing business operations of the Company and management believes the Company remains well-capitalized. Reported Earnings • Aug 11
Second quarter 2023 earnings released: US$0.005 loss per share (vs US$0.005 loss in 2Q 2022) Second quarter 2023 results: US$0.005 loss per share (in line with 2Q 2022). Revenue: US$6.02m (up 42% from 2Q 2022). Net loss: US$5.25m (flat on 2Q 2022). Over the last 3 years on average, earnings per share has increased by 56% per year but the company’s share price has only increased by 14% per year, which means it is significantly lagging earnings growth. Board Change • Jul 01
High number of new directors President, CEO & Director Larry Heaton was the last director to join the board, commencing their role in 2023. New Risk • Jun 20
New major risk - Revenue and earnings growth Earnings have declined by 13% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. This is currently the only risk that has been identified for the company. Announcement • Jun 10
Zomedica Corp. Launches Revolutionary TRUVIEW(TM) Digital Microscope with Advanced Optics, Automated Slide Preparation, and Telepathology Services Zomedica Corp. announced the launch of the revolutionary TRUVIEWTM digital microscopy platform, featuring the proprietary TRUprepTM system that automatically prepares slides, along with LiquiViewTM liquid lens technology that provides best-in-class images. Microscopic examination of blood and cytology fluids is the standard of care in the veterinary industry and is utilized by essentially every veterinary practice. The groundbreaking all-in-one TRUVIEW system combines LiquiView advanced optics, TRUprep automated slide preparation and tele-pathology with an easy-to-use interface to ensure consistent quality to boost veterinarian diagnostic confidence. The LiquiView advanced optics system will provide the highest quality slide images on the market, leading to better diagnostics for the pet. Preparing cytology slides and making blood smear slides can be critically important to cellular investigation and diagnosis. However, the effectiveness and accuracy of that interpretation depend on the quality of the slide. The TRUVIEW microscope features the TRUprep automated slide preparation system, eliminating the need for manual slide preparation because all the traditional manual slide preparation steps, including smearing, drying, fixing, staining, washing and drying, are handled by the TRUprep system, assuring consistent high-quality slides, while saving 5-10 minutes of technician time for each slide to improve productivity and workflow. TRUVIEW's digital imaging and telepathology component is an easy-to-use interface providing veterinarians with multiple diagnostic options, including reading the slide directly on the microscope, reviewing the slide digitally from a remote computer through the Company's myZomedica® web portal, or sending the image to a Zomedica pathologist for external review and consultation. This will result in boosting veterinarian confidence in providing a consistent, reliable diagnostic result. Reported Earnings • May 13
First quarter 2023 earnings released: US$0.007 loss per share (vs US$0.004 loss in 1Q 2022) First quarter 2023 results: US$0.007 loss per share (further deteriorated from US$0.004 loss in 1Q 2022). Revenue: US$5.48m (up 46% from 1Q 2022). Net loss: US$6.39m (loss widened 62% from 1Q 2022). Over the last 3 years on average, earnings per share has increased by 55% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings. Reported Earnings • Mar 17
Full year 2022 earnings released: US$0.017 loss per share (vs US$0.053 loss in FY 2021) Full year 2022 results: US$0.017 loss per share (improved from US$0.053 loss in FY 2021). Revenue: US$18.9m (up 358% from FY 2021). Net loss: US$17.0m (loss narrowed 66% from FY 2021). Over the last 3 years on average, earnings per share has increased by 64% per year but the company’s share price has only increased by 15% per year, which means it is significantly lagging earnings growth. Reported Earnings • Nov 16
Third quarter 2022 earnings released: US$0.005 loss per share (vs US$0.006 loss in 3Q 2021) Third quarter 2022 results: US$0.005 loss per share (improved from US$0.006 loss in 3Q 2021). Revenue: US$4.78m (up US$4.75m from 3Q 2021). Net loss: US$5.00m (loss narrowed 21% from 3Q 2021). Over the last 3 years on average, earnings per share has increased by 71% per year but the company’s share price has fallen by 16% per year, which means it is significantly lagging earnings. Announcement • Nov 03
Zomedica Corp. to Report Q3, 2022 Results on Nov 14, 2022 Zomedica Corp. announced that they will report Q3, 2022 results on Nov 14, 2022 Announcement • Sep 14
Zomedica Corp. Announces Launch of Free T4 Assay for Truforma(R) Diagnostic Platform Zomedica Corp. announced the commercial launch of its newest assay - Free T4 (fT4) - for the TRUFORMA In-Clinic Biosensor Testing Platform. Accurately diagnosing thyroid dysfunction can be a challenge in veterinary practice. Measurement of serum tT4, fT4, and TSH concentrations is currently recommended for the assessment of canine thyroid gland function. However, until now, practitioners have been limited to obtaining reliable fT4 results only from the reference laboratory. The in-clinic TRUFORMA free T4 assay, along with tT4 and TSH, brings the capability to deliver this valuable diagnostic panel directly to the point of care while preventing falsely elevated fT4 concentrations due to sample heating during transport to the reference laboratory. The TRUFORMA panel of thyroid assays - total-T4, TSH, and now free-T4 - offers veterinarians accurate, reliable, and precise results to achieve a more timely, definitive differentiation between healthy dogs and those with thyroid disease, thus allowing for faster diagnosis and treatment. Announcement • Aug 24
Zomedica Corp. Appoints Pamela Nichols to Board of Directors and Audit and Governance Committees Zomedica Corp. announced that Pamela Nichols, DVM has been appointed to its Board of Directors and is joining the Audit and Governance committees. Dr. Nichols is the founder of six successful veterinary hospitals and dog boarding/daycare facilities. Her newest hospital is Animal Care Daybreak in South Jordan Utah, which opened in October of 2019. She earned her doctorate in veterinary medicine at Colorado State University in 1996 and her Canine Rehabilitation Practitioner (CCRP) certification in 2004. She has practiced both general medicine and rehabilitation ever since, and recently added acupuncture to her qualifications. Additionally, she is a past president of the American Animal Hospital Association (AAHA) (2020-2021). Dr. Nichols is an instrument rated commercial pilot and flight instructor. She enjoys coaching both individuals and veterinary teams around the country to find the joy in veterinary medicine again. Dr. Nichols is fluent in Spanish, conversant in Italian and is learning to speak French. As an industry leader, Dr. Nichols believes that resilience, lifelong learning, and positivity are the qualities that most define success. Reported Earnings • Aug 16
Second quarter 2022 earnings released: US$0.005 loss per share (vs US$0.005 loss in 2Q 2021) Second quarter 2022 results: US$0.005 loss per share (vs US$0.005 loss in 2Q 2021). Revenue: US$4.25m (up US$4.23m from 2Q 2021). Net loss: US$5.27m (loss widened 12% from 2Q 2021). Over the last 3 years on average, earnings per share has increased by 73% per year but the company’s share price has only increased by 5% per year, which means it is significantly lagging earnings growth. Announcement • Jul 19
Zomedica Corp. (NYSEAM:ZOM) acquired Substantially All the Assets of Assisi Animal Health, LLC. Zomedica Corp. (NYSEAM:ZOM) acquired Substantially All the Assets of Assisi Animal Health, LLC on July 18, 2022. Greg Blair, Zomedica's Vice President of Business Development & Strategic Planning, led the acquisition initiative for the Company. Maslon LLP acted as legal advisor to Zomedica.
Zomedica Corp. (NYSEAM:ZOM) completed the acquisition of Substantially All the Assets of Assisi Animal Health, LLC on July 18, 2022. Reported Earnings • May 12
First quarter 2022 earnings released: US$0.004 loss per share (vs US$0.041 loss in 1Q 2021) First quarter 2022 results: US$0.004 loss per share (up from US$0.041 loss in 1Q 2021). Net loss: US$3.94m (loss narrowed 89% from 1Q 2021). Over the last 3 years on average, earnings per share has increased by 64% per year but the company’s share price has fallen by 12% per year, which means it is significantly lagging earnings. Announcement • Jan 26
Zomedica Corp. Signs TRUFORMA Distribution Agreement with Miller Veterinary Supply Zomedica Corp. announced that it has signed an agreement with Miller Veterinary Supply ('Miller') for the distribution of TRUFORMA, Zomedica’s first product, planned to begin sales on March 30, 2021. Miller, one of the veterinary industry’s fastest growing businesses, was established in 1920 and now is the oldest wholesale veterinary distributor in the United States. The company currently is managed by a group of veterinary industry veterans. Remaining small and independent allows Miller to provide exceptional customer service by employing knowledgeable people who know how a practice functions and by being very flexible. Not content to rest on their 100-year history, the Company is growing rapidly and expanding aggressively. Under the terms of the distribution agreement, Miller will be representing Zomedica in states ranging from Texas to Maine, concentrated in the eastern and mid-eastern portion of the United States. As previously announced, they will be supported by several Zomedica sales employees in the field assigned to work with the Miller sales representatives to enhance the level of customer service provided relating to TRUFORMA. Zomedica currently is recruiting these support representatives as part of its commercialization preparation. Miller assigns dedicated and educated Inside Sales Specialists and Territory Managers to each customer account. This team always is available to handle each account personally by whatever communication method preferred by the customer. They take pride in their experience and attention to customer needs. Miller provides a seamless experience between online and offline channels. Their online ordering offers speed and convenience, while their sales team always is available to offer solutions and to provide value. Announcement • Jan 05
Zomedica Corp. Appoints Robert Cohen as Chief Executive Officer Zomedica Corp. announced the appointment of Robert Cohen as Chief Executive Officer effective January 1, 2021. Mr. Cohen previously served as the Company’s Interim CEO and as a member of the Board of Directors. Announcement • Oct 07
Zomedica Corp. Appoints Ann Marie Cotter as Chief Financial Officer On October 1, 2020, Zomedica Corp. appointed Ann Marie Cotter as the Company’s Chief Financial Officer and Secretary, effective immediately. Ms. Cotter, 50, has been the Company’s Interim Chief Financial Officer and Corporate Secretary since August 2020. From August 2018 to August 2020, she served as the Company’s Vice President, Finance. Announcement • Sep 26
Zomedica Pharmaceuticals Corp. Approves Board Appointments Zomedica Pharmaceuticals Corp. at its Annual and Special Meeting of Shareholders, approved the appointment of Robert Cohen and Christopher Wolfenberg as directors of the company. Announcement • Jul 08
Zomedica Pharmaceuticals Corp. has completed a Follow-on Equity Offering in the amount of $29.9975 million. Zomedica Pharmaceuticals Corp. has completed a Follow-on Equity Offering in the amount of $29.9975 million.
Security Name: Common Stock
Security Type: Common Stock
Securities Offered: 162,500,000
Price\Range: $0.16
Discount Per Security: $0.0112
Security Name: Series D Warrants
Security Type: Equity Warrant
Securities Offered: 187,500,000
Security Name: Pre-Funded Warrants
Security Type: Equity Warrant
Securities Offered: 25,000,000
Price\Range: $0.1599
Discount Per Security: $0.0112 
